RP-1664
RP-1664 is a selective and orally active PLK4 inhibitor with an IC50 of 3 nM. RP-1664 demonstrates exquisite selectivity over related kinases, including AURKA/B and PLK1. RP-1664 disrupts centriole biogenesis in cancer cells and leads an accumulation of PLK4 and p21 protein. RP-1664 demonstrates increased sensitivity in TRIM37-high-expressing cells or tumors. RP-1664 exhibits anti-tumor activity in breast cancer and neuroblastoma research[1][2].
Product Specifications
CAS Number
[2980682-00-4]
UNSPSC
12352211
Target
Polo-like Kinase (PLK)
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
98.77
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=CC(NC2=NC(N(C3=C(C=C(C=C3F)S(C)(=O)=O)F)C)=NC(C4=CN(C=N4)C)=C2C5CC5)=NN1
Molecular Formula
C23H24F2N8O2S
Molecular Weight
514.55
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
PLK4
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Human Carcinoembryonic antigen-related cell adhesionmolecule 7 (CEACAM7) Elisa Kit
